Pliant Therapeutics is a clinical stage biotechnology company unraveling and targeting the key biological pathways driving fibrosis. By leveraging our powerful product discovery engine, Pliant is developing novel therapeutics that seek to halt progression of fibrotic diseases — ultimately, preserving organ function.
We are combining world-class expertise in TGF-β1 signaling and integrin biology, medicinal chemistry, translational screening technologies, and clinical insights to create best-in-class, tissue-specific inhibitors of fibrotic diseases. Our product engine has the potential to benefit numerous patient populations, as we are targeting fibrosis in a variety of organs and conditions including lung (IPF), liver (primary sclerosing cholangitis, NASH and cirrhosis), kidney (renal fibrosis), skin (scleroderma) and the gastrointestinal tract (stricturing Crohn’s disease).
Pliant’s co-founders include world-renowned researchers from the University of California, San Francisco, who bring broad experience in fibrosis biology and small-molecule chemistry. Together, the Pliant team is dedicated to translating scientific advances in fibrosis biology into novel therapies for patients in need.
At Pliant Therapeutics, we’re driven to transform the lives of patients by developing best-in-class treatments for fibrotic diseases.
“Historically, fibrosis has been studied in silos. At Pliant, we have developed a comprehensive approach that has enabled us to better define pathological processes, identify the key molecular targets, and treat fibrosis. With this approach, we aim to transform the lives of patients with these debilitating diseases.”
– Bernard Coulie, M.D., Ph.D., president and CEO
Pliant Therapeutics, Inc.
260 Littlefield Avenue,
South San Francisco, CA 94080
info@pliantrx.com
650.481.6770